The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Moniman - Was that your 10 share buy 9.7p ?
As suspected,Silverhorse trimmed his 1.2 million holding down to 500k and looking to get back in again sub 9p...no surprise about the sudden change to negative from ultra positive back in October... 🤔
It clear Silverhorse tries to regularly trade this share, going from ramping to deramping in quick succession. News will arrive when it arrives and the day traders will peddle nonsense in between times..JMO
Silver horse, what utter rubbish, it's not 60 days at all, imagine someone wanting to sign a deal with us now.... no sorry we cant do that, we have to wait 60 days as I just bought some shares hahaha
Make your deramping attempts a bit more clever next time
Its 60days here, did you see the larger sells yesterday 9p, should see a fall under 9p soon - any deal is months away anyway so relax
I'm expecting a rise on Monday when I would some of the savvy investors who sold out on the director buys, but back in.
Directors are typically in a blackout period 30 days before any known news or results publications and Monday is the first trading day back after this. We are back in the zone where "news could drop anytime"
Today's RNS has obviously not been taken seriously by anyone other than JS it seems? The only trouble with getting all of these patent protections for Polb-001, are they actually worth anything at all? I could take out a patent on a triangular shaped cricket ball, but is anyone likely going to buy such a product? 🤔 I doubt it. JMO
It's far more likely someone had a mental sell price of 10p and the price went above it, so they sold but that someone could always be an insider of course, like you - impossible to know and not worth dwelling on tbh
MaryB, good luck but as you say it doesn't always work out selling the peaks and buying the troughs, however I still think there is a remote possibility that some insider dealing could be going on here judging by the strange price movements either side of RNS's? I see that someone was prosecuted recently in the Republic of Ireland for using inside information to deal in Hvivo (Open Orphan) shares...I hope that the same isn't going on here! Evidence is almost impossible to gather, but it was proven in the case of Open Orphan. Don't get caught out by any sudden news 😆 🤣. JMO Adyor!
https://www.breakingnews.ie/ireland/first-man-in-states-history-found-guilty-of-insider-trading-after-gambling-retirement-fund-1567087.html
14p on chart by Zakmir
Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.
This AIM-traded firm said the development pertained to POLB 001, a potent phase II-ready p38 MAP kinase inhibitor with promising applications across various disease domains.
It said the approved claims by the US Patent Office encompassed a class of drugs, including POLB 001, intended for the treatment of hypercytokinemia, or cytokine storm, and prevention of hypercytokinemia post-immune response activation, applicable to cytokine storms induced by any disease indication.
Poolbeg said it was actively bolstering its intellectual property portfolio with existing patents covering p38 MAP kinase inhibitors for severe influenza treatment and POLB 001 specifically for hypercytokinemia treatment.
Additionally, the company said it had filed further patent applications to broaden coverage, particularly in cancer immunotherapies, thus augmenting the value and appeal of POLB 001 to potential pharmaceutical partners.
"This notice of allowance is significant for Poolbeg, further strengthening our robust intellectual property for the company's exciting POLB 001 therapy and enhancing its value for potential partners," said chief executive officer Jeremy Skillington.
"POLB 001 has the potential to make breakthrough cancer immunotherapies more accessible to the patients that need them by enabling safer and broader use of these cancer treatments in an outpatient setting.
"I am excited by the potential of POLB 001 to positively impact global health, it has a compelling data package and there is strong unmet need for an effective therapy for cancer immunotherapy-induced cytokine release syndrome with the market potential in this setting alone exceeding $10bn."
It is quite simple although not without risk.
Moniman - it IS what I have been doing !
Re MaryB,
If it were that simple everyone would do it, I think my insider dealing is possibly more closer to the truth judging by pre RNS movements over a period of time? But impossible to prove either way with AIM traded shares. JMHO ADYOR!
Is this truly a game-changer???
why sellers?
precursor to patent and Sp goes down.
looking to buy when this settles....
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, commented: "This Notice of Allowance is significant for Poolbeg, further strengthening our robust intellectual property for the Company's exciting POLB 001 therapy and enhancing its value for potential partners. POLB 001 has the potential to make breakthrough cancer immunotherapies more accessible to the patients that need them by enabling safer and broader use of these cancer treatments in an outpatient setting. I am excited by the potential of POLB 001 to positively impact global health, it has a compelling data package and there is strong unmet need for an effective therapy for cancer immunotherapy-induced Cytokine Release Syndrome with the market potential in this setting alone exceeding US$10 billion.
Https://www.voxmarkets.co.uk/rns/announcement/ea5ba077-b0cc-4587-9265-f80ea7f32b22/
Poolbeg Pharma plc
Poolbeg Pharma plc (POLB.L) Share Price & News
GBX 9.870
0.170 (1.72%)
Last updated 10:16
Price Snapshot
Last Trades
BID
9.600
-
10.000
ASK
HIGH
10.400
OPEN
10.150
VOL
1,300,693
MKT CAP
49.33M
LOW
9.610
CLOSE
9.700
SHARES IN ISSUE
500.00M
2W1M3M1Y
Profile
Financials
RNS
More...
Poolbeg Pharma plc RNS
March 20, 2024
07:00 POLB - Poolbeg Pharma PLC - POLB 001 US Patent Update
Twitter
February 22, 2024
07:00 POLB - Poolbeg Pharma PLC - Director/PDMR Shareholding
Twitter
February 19, 2024
13:42 POLB - Poolbeg Pharma PLC - Director Share Purchase
Twitter
February 15, 2024
07:00 POLB - Poolbeg Pharma PLC - Board Role Change and Launch of EIP
Twitter
February 12, 2024
07:00 POLB - Poolbeg Pharma PLC - Market Opportunity for POLB 001 for CRS
Twitter
January 17, 2024
07:00 POLB - Poolbeg Pharma PLC - Further data shows POLB001 potential in cancer CRS
Twitter
December 20, 2023
07:00 POLB - Poolbeg Pharma PLC - RSV AI Drug Candidate Analysis Update
Twitter
December 11, 2023
07:00 POLB - Poolbeg Pharma PLC - POLB 001 Data Presented at ASH
Twitter
November 30, 2023
07:00 POLB - Poolbeg Pharma PLC - Directorate Change
Twitter
November 21, 2023
07:00 POLB - Poolbeg Pharma PLC - Immunomodulator II patent granted in Japan
Twitter
November 16, 2023
07:00 POLB - Poolbeg Pharma PLC - POLB 001 LPS Trial Data to be Presented at IUIS
Twitter
November 09, 2023
07:00 POLB - Poolbeg Pharma PLC - Former Amryt Pharma Leadership Team join Poolbeg
Twitter
November 03, 2023
07:05 POLB - Poolbeg Pharma PLC - POLB001 Data to be Presented at ASH Annual Meeting
Twitter
November 01, 2023
07:00 POLB - Poolbeg Pharma PLC - POLB 001 Oncology Programme Update Meeting
Twitter
October 26, 2023
07:00 POLB - Poolbeg Pharma PLC - SAB Endorses Influenza Drug Targets
Twitter
October 17, 2023
07:00 POLB - Poolbeg Pharma PLC - Poolbeg Partners with a Nasdaq-Listed Biopharma
Twitter
September 29, 2023
07:00 POLB - Poolbeg Pharma PLC - Favourable Conclusion of Patent Opposition
Twitter
September 20, 2023
07:00 POLB - Poolbeg Pharma PLC - Immunomodulator I Patent Portfolio Strengthened
Twitter
September 19, 2023
07:00 POLB - Poolbeg Pharma PLC - Immunomodulator I Patent Opposition Withdrawal
Twitter
September 13, 2023
07:00 POLB - Poolbeg Pharma PLC - Interim results for the six months to 30 June 2023
Twitter
June 29, 2023
07:00 POLB - Poolbeg Pharma PLC - AI led programme identifies influenza drug targets
Twitter
June 22, 2023
07:00 POLB - Poolbeg Pharma PLC - Oral Vaccine Programme Moves Forward
Twitter
May 24, 2023
07:00 POLB - Poolbeg Pharma PLC - Board Appointment
Twitter
May 11, 2023
14:27 POLB - Poolbeg Pharma PLC - Results of Annual General Meeting
Twitter
April 12, 2023
07:00 POLB - Poolbeg Pharma PLC - Annual Report & AGM Notice
Twitter
March 30, 2023
07:00 POLB - Poolbeg Pharma PLC - Results for the year ended 31 December 2022
Twitter
March 10, 2023
07:00
I'm i reading this right..... £1Billion revenue
30 /70 on a tighter range
Buy 200000@9p
Sell 140000 @ 10.2195p
60000 at £3794.60 = 6.32p
Anything is possible.
You might well be right 'troutisout'. I'd read the line
'for preventing hypercytokinaemia in a patient after an immune response has been triggered' as covering oncology - and the further applications as relating to specific treatment / cancers... But it could equally be your reading of this... Maybe a question for the next presentation? (though possibly one they can't answer in full).
Or simply averaging down while building up a position.
Buy 200000@8.14p
Sell 100000@ 11.35p
Remaining Holding 100000 @ 5.0233p incl comms
Certainly what I am doing.
Is there a repetitive pattern of potential insider dealing going on here? Share Price starts rising a couple of days before an RNS, price spikes first thing and then someone seems to dump blocks of shares for a quick profit it appears? 😳 Maybe I'm just a tad to sceptical but AIM is definitely a little Wild West. JMO Adyor!
I am not sure this covers the Oncology side, it states "any disease indication", then states that further applications have been filed, the cancer immunotherapies mentioned in that bit. For them CRS is not disease based, but a side effect of the treatment.
I suspect it will be treated as 'business as usual'...
However, an American patent covering cytokine storm is seriously good news. As Jeremy says - this is a $10billon market for cancer immunotherapy triggered CS alone.
This investor is happy today :-)